Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass

NCT07272837 | Recruiting

• 1 other identifier: Pro00153724
• Study Type: observational
• Target: 50
• Locations: 1 country
• Sites: 1

Brief Summary

The aim of this study is to use advanced MRI scans to track changes in both muscle and fat in the body and heart over a 12-month period in individuals starting semaglutide. By doing so, we hope to gain a clearer understanding of how semaglutide affects muscle health and function. Our goal is to ensure the medication supports long-term well-being, particularly for people who may be at higher risk of muscle loss. This study involves (3) in-person study visits. At each visit, participants will be asked to:

• Undergo magnetic resonance imaging (MRI) while resting and during exercise to take pictures of their heart, abdomen, and legs.
• Complete tests to assess balance, sit-to-stand, walking speed, and handgrip strength.
• Complete questionnaires related to demographics, health information, physical activity, and nutrition.
• Have a blood sample collected from a vein in your arm.
• Have your blood levels assessed through three finger pricks.
• Complete three days of food records.

Conditions

Type 2 Diabetes; Obesity; Semaglutide; GLP-1; Diabetes

Keywords

Semaglutide; Type 2 Diabetes; Diabetes; Obesity; Body Composition; Muscle Mass; Skeletal Muscle Mass; Cardiac Muscle Mass; GLP-1 Receptor Agonist; GLP-1; MRI; Magnetic Resonance Imaging

Outcome Measures

Primary Outcomes (1)

• Changes in skeletal and cardiac muscle mass

  12 months

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Individuals who are starting semaglutide and are able to attend study visits at the Mazankowski Alberta Heart Institute.

You may qualify if:

• Adults 18-80 years of age
• Starting semaglutide for type 2 diabetes or weight loss
• Able to safely undergo an MRI scan (including meeting the physical requirements for MRI equipment)

You may not qualify if:

• Current use of semaglutide for more than 2 weeks
• Major recent heart issues or other severe health conditions
• Concerns related to MRI use (including magnetic implants, pacemaker, severe claustrophobia)
• Dependence on a mobility aid (unable to participate in exercise MRI)

Sponsors & Collaborators

• University of Alberta: lead

Study Sites (1)

Mazankowski Alberta Heart Institute

Edmonton, Alberta, T6G 0M9, Canada

RECRUITING

Related Links

• Study information and pre-screening survey

Biospecimen

Retention: SAMPLES WITH DNA

Blood samples will be retained for up to 10 years after the completion of the main study.

MeSH Terms

Conditions

Diabetes Mellitus, Type 2; Obesity; Diabetes Mellitus

Condition Hierarchy (Ancestors)

Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Endocrine System Diseases; Overweight; Overnutrition; Nutrition Disorders; Body Weight; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Central Study Contacts

Krista Jong, RD, BSc

CONTACT

780-492-9010; glimmer@ualberta.ca

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 26, 2025
• First Posted: December 9, 2025
• Study Start: April 14, 2026
• Primary Completion (Estimated): December 31, 2027
• Study Completion (Estimated): April 30, 2028
• Last Updated: April 20, 2026

Record last verified: 2026-04

Data Sharing

• IPD Sharing: Will not share

Locations

CA (1)